Literature DB >> 4612168

Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia.

G W Santos, P J Tutschka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4612168

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  12 in total

1.  Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

Authors:  Jeannine S McCune; Paolo Vicini; David H Salinger; Paul V O'Donnell; Brenda M Sandmaier; Claudio Anasetti; Donald E Mager
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-06       Impact factor: 3.333

2.  A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.

Authors:  Jeannine S McCune; Erica L Woodahl; Terry Furlong; Barry Storer; Joanne Wang; Shelly Heimfeld; H Joachim Deeg; Paul V O'Donnell
Journal:  Cancer Chemother Pharmacol       Date:  2011-09-11       Impact factor: 3.333

3.  Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model.

Authors:  Elizabeth M Kang; Matthew M Hsieh; Mark Metzger; Allen Krouse; Robert E Donahue; Michel Sadelain; John F Tisdale
Journal:  Exp Hematol       Date:  2006-02       Impact factor: 3.084

4.  Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.

Authors:  Eucario Leon-Rodriguez; Monica M Rivera-Franco
Journal:  Int J Hematol       Date:  2016-10-08       Impact factor: 2.490

5.  Ifosfamide and ACNU in experimental allogeneic bone marrow transplantation.

Authors:  W Gassmann; A Erbersdobler; L Uharek; B Glass; H Löffler; W Mueller-Ruchholtz
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Matthew Whayman; John A Turton
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

7.  Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.

Authors:  H P Bhagwatwar; S Phadungpojna; D S Chow; B S Andersson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

8.  Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts.

Authors:  Matthew M Hsieh; Saskia Langemeijer; Aisha Wynter; Oswald A Phang; Elizabeth M Kang; John F Tisdale
Journal:  Exp Hematol       Date:  2007-07-09       Impact factor: 3.084

Review 9.  Busulfan in hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742

10.  Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs.

Authors:  J D Down; A Boudewijn; J H Dillingh; B W Fox; R E Ploemacher
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.